Methods and uses of leptin in immune modulation
OwnerYaron Ilan, Eran Elinavinventors
Life of this patent
Estimating the term…
Abstract
The present invention describes the use of leptin for the immune modulation of the Th1/Th2 response. One aspect of the invention provides for a shift in the Th1/Th2 cell balance towards pro-inflammatory cytokine producing cells. This shift results from an increase in the levels, expression and/or the activity of leptin. Another aspect of the invention provides for a shift in the Th1/Th2 cell balance towards anti-inflammatory cytokine producing cells. This shift results from a decrease in the levels, expression and/or the activity of leptin. The shifting of the Th1/Th2 balance provides a method for the treatment of a variety of diseases and disorders.
Claims51
A method for immuno-modulation of the Th1/Th2 cell balance, in a subject in need thereof, comprising the step of modulating the levels, the expression and/or the activity of leptin in said subject.
A method for the treatment of an immune-related disorder in a subject in need thereof, comprising the step of administering to said subject an immuno-modulatory effective amount of leptin or any homologues, derivatives, functional fragments or mixture thereof, an expression vector comprising nucleic acid sequence encoding for leptin or any functional fragments thereof or a composition comprising the same.
Use of leptin or any homologues, derivatives, functional fragments or mixture thereof, an expression vector comprising nucleic acid sequence encoding for leptin or any functional fragments thereof for the preparation of a composition for shifting the Th1/Th2 cell balance toward pro-inflammatory cytokine producing cells.
Use of leptin or any homologues, derivatives, functional fragments or mixture thereof, an expression vector comprising nucleic acid sequence encoding for leptin or any functional fragments thereof for the preparation of a medicament for the treatment of an immune-related disorder.
The method according to clam 27, wherein said subject is a mammalian subject suffering of an immune-related disorder.
A method for the treatment of an immune-related disorder in a subject in need thereof, comprising the step of administering to said subject an immuno-modulatory effective amount of any one of an antibody specific for leptin and a nucleic acid sequence capable of inhibiting the expression of leptin selected from the group consisting of leptin anti-sense nucleic acid sequence, a ribozyme, a small interfering RNA (siRNA) specific for leptin and a composition comprising the same.
Use of any one of an antibody specific for leptin and a nucleic acid sequence capable of inhibiting the expression of leptin selected from the group consisting of leptin anti-sense nucleic acid sequence, a ribozyme and a small interfering RNA (siRNA) specific for leptin for the preparation of a composition for shifting the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells.
Use of any one of an antibody specific for leptin and a nucleic acid sequence capable of inhibiting the expression of leptin selected from the group consisting of leptin anti-sense nucleic acid sequence, a ribozyme, a small interfering RNA (siRNA) specific for leptin for the preparation of a medicament for the treatment of an immune-related disorder.
A method for the treatment of immune-related disorders in a mammalian subject in need of such treatment, by manipulating NKT cell population of said subject, wherein manipulation of said NK T cell population results in modulation of the Th1/Th2 cell balance, said method comprises the steps of:
- a. obtaining NK T cells from said subject;
- b. ex vivo educating the NK T cells obtained in step (a) such that the resulting educated NK T cells have the capability of modulating the Th1/Th2 cell balance;
- and
- c. re-introducing to said subject the educated NK T cells obtained in step (b) which are capable of modulating the Th1/Th2 cell balance.
A therapeutic composition for the treatment of an immune-related disorder in a mammalian subject, which composition comprises as an effective ingredient ex vivo educated autologous NK T cells capable of modulating the Th1/Th2 cell balance, and optionally further comprising pharmaceutically acceptable carrier, diluent, excipient and/or additive.
Dependencies are inferred from the claim text.